Overview

A Pharmacokinetic Study of Saroglitazar Magnesium in Subjects With Severe Renal Impairment and Normal Renal Function

Status:
Recruiting
Trial end date:
2022-03-30
Target enrollment:
Participant gender:
Summary
This will be a Phase 1, Open-label Study of Participants with Normal Renal Function and Participants with Sever Renal Impairment.
Phase:
Phase 1
Details
Lead Sponsor:
Zydus Discovery DMCC
Zydus Therapeutics Inc.